Lalan Wilfong, MD, executive vice president, Value Based Care & Quality Programs, Texas Oncology, and co-chair, Payment Reform, Community Oncology Alliance, discusses implications of quality metrics in cancer care and what perspectives on the topic he is looking forward to hearing at the 2021 Community Oncology Conference.
Lalan Wilfong, MD, is the executive vice president of Value Based Care & Quality Programs at Texas Oncology and Payment Reform Co-Chair at the Community Oncology Alliance.
Transcript
For the 2021 Community Oncology Conference, a panel will discuss quality measurement in cancer care. How has use of quality metrics influenced the way in which cancer care has been delivered and perceived in recent years?
Quality metrics have influenced the way that we measure and perceive cancer care by focusing us more on what means most to patients, and how do we improve the outcomes that we provide versus just managing patients as best we see.
Things like metrics in the Oncology Care Model for reducing hospitalizations and reducing ED [emergency department] visits makes us think through the entire patient care continuum versus focusing on just what's happening that day with a patient.
So, it has led to significant changes in the way that we think and deliver cancer care. That being said, I am looking forward to the session on quality measures because we need to think through better how we reduce the burden on reporting from practices, which is a significant issue for reporting quality metrics, while at the same time really focusing on those that impact outcomes the most.
What perspectives are you looking forward to hearing during the panel discussion?
I think for my panel discussion, we're going to talk about the new model for cancer care, and one of the things we're going to discuss is how it needs to be flexible. Different practices, different payers, patient populations need different focus to continue to improve the value we provide them.
Some practices are very sophisticated, some payers are sophisticated—some are not. So, how do you get everybody moving forward? And that's one of the things that we will discuss is the flexibility needed for us all to get there, because there's not going to be a one-size fits all model that we can take forward. So I'm really looking forward to discussing that and hearing opinions on that process.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Panel Addresses Minority Physician Shortage, Maternal Health, at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More